GERON CORP Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
GERON CORP (GERN) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $3.58 million for the 12-month period ending 2020-12-31, per its 10-K filed 2023-03-16.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2023-03-16
- GERON CORP right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $3.58M, a 44.56% increase from fiscal 2019.
- GERON CORP right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $2.47M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|
| 2020-12-31 | $3.58M 10-K · filed 2023-03-16 |
| 2019-12-31 | $2.47M 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |